SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
EXEL

Exelixis, Inc. (NASDAQ:EXEL)

US · Delayed Price · Currency is USD
Also listed: 0IJO.L, EX9.DEHealthcare · Biotechnology
$64.63-$1.20 (-1.82%)
 
Market cap
$16.2B
Insider Score
Health Score
Analyst consensus
Listed since
Apr 17, 2000
Market Cap$16.25B+53.0%
Revenue (ttm)$2.50B+9.1%
Net Income$885.14M+30.6%
EPS$3.34+40.9%
Shares Out251.36M
PE Ratio18.73
Forward PE15.35
Dividendn/a
Ex-Dividend Daten/a
Volume2,194,294
Open$65.90
Previous Close$65.83
Day's Range$64.44 - $66.94
52-Week Range$39.71 - $73.69
Beta0.42
AnalystsHold
Price Target$54.20(-16.14%)
Earnings DateFeb 9, 2027

About EXEL

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

Address
1851 Harbor Bay Parkway, Alameda, CA, 94502, US
Market Cap
16.25 billion
Employees
1,077
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$11.15M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
3 Buy5 Hold0 SellAvg target $54.88 (-15.1%)

8 firms rating EXEL in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From EXEL’s reported statements · Q4 2026 (trailing 12 months)

Next catalysts

1 Day
-1.82%
5 Days
-6.62%
1 Month
-1.04%
6 Months
+28.87%
1 Year
+52.97%

$EXEL stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of EXEL by members of U.S. Congress

Donna ShalalaHouseSale$1.00K – $15.00KJun 4, 2019
Donna ShalalaHouseSale$1.00K – $15.00KApr 16, 2019
Donna ShalalaHousePurchase$1.00K – $15.00KFeb 6, 2019
Donna ShalalaHousePurchase$1.00K – $15.00KJan 9, 2019

Recently reported changes in EXEL holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by EXEL's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

EXEL Estimated quarterly lobbying spending

Source: U.S. Senate LDA

EXEL Revenue by Segment or Geography

$1.57BTotal
Gross product revenues$853.72M54.35%
Net product revenues$604.92M38.51%
License revenues$58.41M3.72%
Collaboration revenues$53.77M3.42%

As of: Q4 2026 (Oct 2, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New EXEL patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to EXEL from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in EXEL

IJHiShares Core S&P Mid-Cap ETF$577.01M
VTIVanguard Morningstar Total Stock Market ETF$409.93M
VBVanguard Morningstar Small-Cap ETF$366.22M
XMHQInvesco S&P MidCap Quality ETF$205.78M
VBKVanguard Morningstar Small-Cap Growth ETF$204.84M
VXFVanguard Extended Market ETF$195.01M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from EXEL’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0.27
Analyst Ratings
32% of score
73
News & Sentiment
20% of score
72

News check: Pipeline progress and FDA decision catalysts dominate coverage; mixed valuation opinions offset by concrete clinical developments and business momentum.

Recent Insider Activity

Buys
0
Sells
10
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BOUTCapForce IBD Breakout Opportunities ETF3.90%
FBTFirst Trust NYSE Arca Biotechnology Index Fund3.76%
XMHQInvesco S&P MidCap Quality ETF3.76%
CANCTema Oncology ETF3.74%
IDNAiShares Genomics Immunology and Healthcare ETF3.74%
NEWZStockSnips AI-Powered Sentiment US All Cap ETF3.71%
MCOWPacer Funds Trust - Pacer S&P MidCap 400 Quality FCF Aristocrats ETF3.71%
SAWGAAM Sawgrass US Large Cap Quality Growth ETF3.48%
GLRYInspire Growth ETF3.41%
ASCEAllspring SMID Core ETF3.39%
PBEInvesco Biotechnology & Genome ETF3.34%
ACTSFIS Tactical Equity ETF3.33%

Weight is the stock’s share of each fund’s holdings.